The question of the use of Andexxa, a reversal agent for Factor Xa Inhibitors, has been batting around my brain for a few months now. We are in the unfortunate position of having a drug with very questionable evidentiary support but with an FDA labelled indication. I received an email from the lead author of paper just published in Neurocritical Care.
- Peled et al. Key Points to Consider When Evaluating Andexxa for Formulary Addition. Neurocrit Care 10.1007/s12028-019-00866-6
Dr. Harry Peled is the medical director of Cardiology and Critical Care at St Jude Medical Center in California. Relevantly, he is also chair of the Pharmacy an Therapeutics Committee.
I would love to hear your thoughts on this issue–place them in the comments below.
See Also
Update:
Now on to the Podcast…
Podcast: Play in new window | Download (Duration: 19:00 — 17.8MB) | Embed
Subscribe: Apple Podcasts | Google Podcasts | Spotify | RSS | More
Professor
Chief, Division of Emergency Critical Care
Director, Resuscitation and Acute Critical Care Unit
Stony Brook Medicine
Stony Brook, NY, USA
No conflicts of interest (coi).
- EMCrit 290 – Decompensated Hypothyroidism and Myxedema with Dr. Arti Bhan - January 23, 2021
- EMCrit 289 – Ketamine Only Intubation Paper with Brian Driver - January 12, 2021
- EMCrit 288 – Neurogenic Shock & Should we be Using Vasopressors for Hemorrhagic Shock? - December 29, 2020